Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: The FRUIT-RCT

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 197, Issue , 2016, Pages 168-173

  Van Hoorn, Marion E ^a   Hague, William M ^b   Van Pampus, Mariëlle G ^c   Bezemer, Dick ^a   De Vries, Johanna I P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Antiphospholipid antibodies; Aspirin; Low molecular weight heparin; Pre eclampsia; Randomised controlled trial

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; DALTEPARIN; LUPUS ANTICOAGULANT; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ALLERGY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATTRIBUTABLE RISK; BIRTH WEIGHT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HEMATOMA; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; LABOR INDUCTION; MATERNAL HYPERTENSION; MEDICAL HISTORY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PAIN; PREECLAMPSIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SKIN MANIFESTATION; SMALL FOR DATE INFANT; SWELLING; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPHILIA; AUSTRALIA; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; FIRST TRIMESTER PREGNANCY; HYPERTENSION, PREGNANCY-INDUCED; NETHERLANDS; NEWBORN; PRE-ECLAMPSIA; PREGNANCY; PREMATURITY; SWEDEN; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; AUSTRALIA; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; GESTATIONAL AGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; INTENTION TO TREAT ANALYSIS; NETHERLANDS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREMATURE BIRTH; RECURRENCE; SWEDEN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84960092725     PISSN: 03012115     EISSN: 18727654     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2015.12.011     Document Type: Article

References (19)

1. W.A. Wilson, A.E. Gharavi, T. Koike, and et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop Arthritis Rheum 42 1999 1309 1311
2. S. Miyakis, M.D. Lockshin, T. Atsumi, and et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J Thromb Haemost 4 2006 295 306
3. M.P. Rambaldi, F. Mecacci, S. Guaschino, and M.J. Paidas Inherited and acquired thrombophilias Reprod Sci 21 2014 167 182
4. R. Rai, H. Cohen, M. Dave, and L. Regan Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) Br Med J 314 1997 253 257
5. R.G. Farquharson, S. Quenby, and M. Greaves Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment Obstet Gynecol 100 September 2002 408 413 Erratum in: Obstet Gynecol 2002, 100:1361
6. C.A. Laskin, K.A. Spitzer, C.A. Clark, and et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial J Rheumatol 36 2009 279 287
7. D.W. Branch, R.M. Silver, J.L. Blackwell, J.C. Reading, and J.R. Scott Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience Obstet Gynecol 80 1992 614 620
8. H. Yamada, T. Atsumi, G. Kobashi, and et al. Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes J Reprod Immunol 79 2009 188 195
9. J. Nodler, S.R. Moolamalla, E.M. Ledger, B.S. Nuwayhid, and Z.D. Mulla Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset BMC Pregnancy Childbirth 16 2009 9 11
10. W.H. Kutteh Antiphospholipid antibody - associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose heparin alone Am J Obstet Gynecol 174 1996 1584 1589
11. J.I. de Vries, M.G. van Pampus, W.M. Hague, P.D. Bezemer, and J.H. Joosten J Thromb Haemost 10 2012 64 72
12. R. Skjaerven, H.K. Gjessing, and L.S. Bakketeig Birthweight by gestational age in Norway Acta Obstet Gynecol Scand 79 2000 440 449
13. E.N. Harris Special report: the Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group Am J Clin Pathol 94 1990 476 484
14. J.J. Kalk, A.J. Huisjes, C.J. de Groot, and et al. Recurrence rate of pre-eclampsia in women with thrombophilia influenced by low-molecular-weight heparin treatment Neth J Med 62 2004 83 87
15. E. Bujold, S. Roberge, Y. Lacasse, and et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis Obstet Gynecol 116 2010 402 414
16. L.M. Askie, L. Duley, D.J. Henderson-Smart, and et al. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data Lancet 369 2007 1791 1798
17. M.A. Rodger, W.M. Hague, J. Kingdom, and et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial Lancet 384 2014 1673 1683
18. M.A. Rodger, N.J. Langlois, J.I. de Vries, and et al. Low-molecular-weight heparin for prevention of placenta-mediated pregnancy complications: protocol for a systematic review and individual patient data meta-analysis (AFFIRM) Syst Rev 3 2014 69
19. M.A. Rodger, M. Carrier, G. Le Gal, and et al. Low-Molecular-Weight Heparin for Placenta-Mediated Pregnancy Complications Study Group. Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications Blood 123 2014 822 828